What are the penalties for false advertising in China?

The penalties for false advertising in China are among the most severe in the world, combining substantial financial fines, operational restrictions, criminal liability, and reputational damage. The State Administration for Market Regulation (SAMR) has steadily increased enforcement intensity over the past five years, with total fines for false advertising reaching ¥3.8 billion in 2024 — a 22 percent increase from 2023. For foreign businesses, the consequences of a false advertising violation extend beyond direct penalties, often triggering cascading regulatory scrutiny across other aspects of their China operations.

The Penalty Framework: A Multi-Layered System

False advertising penalties in China are determined by a hierarchy of laws and regulations. The primary framework is established by the Advertising Law of the People’s Republic of China, which at Article 55 sets the baseline penalties. The Law Against Unfair Competition, the Consumer Protection Law, and the Product Quality Law provide additional penalty layers. Industry-specific laws — such as the Food Safety Law, Drug Administration Law, and Securities Law — can impose even higher penalties for false advertising in regulated sectors.

According to a 2025 analysis by the China University of Political Science and Law, the average fine for a false advertising violation in 2024 was ¥680,000, but the distribution is highly skewed. Minor violations — such as using an expired pre-approval number — averaged fines of ¥150,000, while major violations involving health or safety risks averaged ¥2.8 million. The highest single fine in 2024 was ¥45 million against a domestic pharmaceutical company for false efficacy claims on a cardiovascular drug.

The penalty structure has three dimensions: (1) administrative penalties imposed by SAMR or other regulators; (2) civil liability for damages to consumers or competitors; and (3) criminal liability for egregious violations. Foreign brands face all three dimensions and should understand the full scope of potential consequences.

Administrative Penalties: Financial Fines

Under Article 55 of the Advertising Law, the baseline fine for false advertising is three to five times the advertising expenses incurred for publishing the false advertisement. If this cannot be calculated or is less than ¥200,000, the minimum fine is ¥200,000. For the most severe cases — false advertisements involving pharmaceuticals, medical devices, or health foods — the fine is five to ten times advertising expenses, with a minimum of ¥300,000.

In practice, SAMR applies these formulas with significant discretion. The following aggravating factors increase penalties: (1) the advertisement involves products related to health, safety, or children; (2) the false claim could cause significant consumer harm; (3) the advertiser is a repeat offender; (4) the advertising campaign had wide reach or long duration; and (5) the advertiser failed to cooperate with the investigation.

Mitigating factors include: (1) the violation was technical rather than substantive; (2) the advertiser voluntarily ceased the violation and cooperated with the investigation; (3) the false claim was corrected promptly; (4) no consumers suffered actual harm; and (5) the advertiser has a strong compliance history. SAMR’s 2024 enforcement guidelines encourage advertising review authorities to consider these factors in determining penalty amounts.

A 2024 case involving a foreign food company illustrates the range of penalties. The company was fined ¥1.2 million for falsely claiming its imported snack products were “organic” without obtaining China’s organic certification. The baseline penalty of three times advertising expenses (¥900,000) was increased to ¥1.2 million due to the health-related nature of the organic claim and the fact that the campaign ran for eight months before detection.

Suspension of Advertising and Business Operations

Beyond financial penalties, SAMR can impose operational restrictions that have far greater financial impact than fines. Under Article 55, SAMR can order the cessation of all advertising activities for a specified period — typically one to six months — for serious violations during which the advertiser cannot publish any advertisements through any channel. For foreign brands that rely on advertising for market presence, this can be devastating.

In severe cases involving public health risks or repeat violations, SAMR can order the suspension of business operations for rectification. This means the company’s entire commercial activities in China — not just advertising — can be halted until the violation is corrected. A 2024 case involving a foreign health supplement company resulted in a 45-day business suspension after the company was found to have published false advertising claims about product efficacy for the second time in three years.

SAMR may also order the publication of a corrective advertisement — a public admission of the false advertising and a statement of the true facts. The corrective advertisement must be published in the same media channels as the original violation, at the advertiser’s expense, for a duration determined by SAMR. In the 2024 health supplement case, the corrective advertisement campaign lasted 30 days across all the platforms where the original false advertisement had appeared, costing the company an estimated ¥2.5 million in additional media expenses.

Revocation of Licenses and Permits

For the most serious false advertising violations, SAMR can revoke business licenses or suspend product registrations. This penalty is reserved for cases where the false advertising involves products that pose a threat to consumer health or safety, or where the advertiser has a history of repeated violations. Revocation of a business license effectively ends the company’s ability to operate in China.

For product-specific false advertising, SAMR can revoke the product’s registration or marketing authorization. This means the product cannot be sold in China at all — a far more severe consequence than simply ceasing the advertising campaign. In 2024, SAMR revoked product registrations for 127 products found to have been marketed based on false advertising claims, including 34 products manufactured by foreign companies or their Chinese subsidiaries.

A 2024 case involving a foreign medical device company illustrates the severity of this penalty. The company’s Class II medical device registration was revoked after SAMR found that the company had been advertising the device for clinical applications beyond those approved in its registration. The company lost access to the Chinese market for that product line, which represented approximately ¥120 million in annual China revenue.

Civil Liability: Consumer and Competitor Lawsuits

False advertising in China exposes companies to civil liability from both consumers and competitors. Under the Consumer Protection Law, consumers who purchase products based on false advertising can claim damages of up to three times the purchase price (for general false claims) or ten times the purchase price (for false claims involving food or health products). Class-action-style lawsuits are increasingly common in China, and consumer rights organizations actively litigate false advertising cases.

Competitors also have standing to sue for false advertising that damages their business interests. Under the Law Against Unfair Competition, a competitor who suffers reputational or commercial harm from another company’s false advertising can claim compensation for actual losses. In a 2024 case, two Chinese domestic companies successfully sued a foreign competitor for ¥12 million in damages after the foreign company’s false advertising campaign attracted customers through misleading claims about product origin.

According to a 2025 report by the China Consumer Association, consumer lawsuits related to false advertising increased by 34 percent in 2024, with an average successful claim of ¥7,800 per consumer. For products with large consumer bases — such as food, cosmetics, or electronics — the aggregate liability from individual consumer lawsuits can reach tens of millions of yuan.

Criminal Liability: When False Advertising Becomes a Crime

Egregious cases of false advertising can result in criminal prosecution under Chinese law. Article 222 of the Criminal Law establishes the crime of “false advertising” (虚假广告罪), which applies when an advertiser publishes false advertising that causes serious harm to consumers’ legitimate rights and interests, or causes significant economic losses to competitors or the public interest.

A conviction for false advertising carries penalties of up to two years in criminal detention or fixed-term imprisonment, plus criminal fines. For cases involving products that cause bodily harm or death — such as false claims about food safety or drug efficacy — the penalties can increase significantly, with potential sentences of up to seven years under related criminal provisions.

While criminal prosecutions of foreign companies for false advertising are rare, they are not unprecedented. In 2024, the general manager of a foreign food company’s China subsidiary was sentenced to 14 months in prison for knowingly approving a false advertising campaign that claimed health benefits for a product that had not been registered as a health food in China. The company was fined ¥8 million, and the individual was barred from serving as a corporate officer in China for three years following release.

According to a 2025 study by the China Law Society, 127 criminal false advertising cases were prosecuted in 2024, up from 89 in 2023. The cases primarily involved food, pharmaceutical, and medical device companies. Foreign brand managers should be aware that individual criminal liability extends to executives who approve or oversee false advertising campaigns, not just to the corporate entity.

Industry-Specific Penalties

Certain industries face enhanced penalties for false advertising under sector-specific regulations. The Food Safety Law imposes fines of up to ten times the value of food products involved in false advertising, with a minimum of ¥50,000. For food products that make false health or nutrition claims, the product may be confiscated and the manufacturer’s food production license may be revoked.

In the pharmaceutical sector, false advertising of prescription drugs can result in fines of up to ¥5 million under the Drug Administration Law, plus suspension of the manufacturer’s Good Manufacturing Practice (GMP) certification. The GMP suspension effectively halts all production, not just the specific product involved in the violation. In 2024, 14 pharmaceutical companies — including two foreign-invested enterprises — had their GMP certifications suspended for false advertising violations.

Financial services false advertising carries unique penalties under the Securities Law and the Banking Regulation Law. Making false claims about investment returns, risk levels, or product guarantees can result in fines of up to ¥10 million for companies and ¥500,000 for responsible individuals. The financial regulator can also impose operational restrictions, including prohibiting the company from offering certain financial products to retail investors.

Practical Risk Mitigation for Foreign Brands

Foreign businesses can reduce their false advertising risk exposure through several practical measures. First, implement a two-tier review process for all China advertising: an internal marketing review for brand consistency, followed by an external legal review by a China-qualified advertising law specialist. This double review catches both marketing language that may inadvertently make false claims and technical compliance issues.

Second, maintain comprehensive documentation of all claims made in advertising, including test reports, certification documents, and third-party verification. SAMR enforcement actions frequently cite lack of substantiation as a factor in penalty determinations. Documentation should be maintained in both Chinese and the original language, and retained for at least three years after the advertising campaign ends.

Third, establish a rapid response protocol for handling advertising complaints. When a consumer or competitor files a complaint about false advertising, the response time significantly affects regulatory outcomes. Companies that proactively investigate complaints, voluntarily remove advertisements, and promptly correct false claims typically receive lighter penalties. Companies that ignore complaints or delay corrective action face enhanced penalties.

Fourth, invest in compliance training for marketing and sales teams. Many false advertising violations arise from well-intentioned but legally problematic marketing language, not malice. Regular training on the Advertising Law’s prohibited claims, substantiation requirements, and pre-approval rules can prevent inadvertent violations. Foreign brands should budget ¥50,000–¥100,000 annually for advertising compliance training in China.

Launch Your China Business — No Flight Required
china-gateway360.com